Relapsing-remitting multiple sclerosis

18 trials 5 recruiting MedDRA PT
18 Registered trials
5 Recruiting
14 Unique sponsors
25 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
H Endocrinology (ATC H) 4
L Oncology (ATC L) 11
N Neurology/Psychiatry (ATC N) 3
R Respiratory (ATC R) 3
A Gastroenterology (ATC A) 2
G Urology/Gynaecology (ATC G) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Corticosteroid 2 substances
Monoclonal antibody (immune, humanized) 2 substances
Interferon 2 substances
Analgesic / antipyretic 1 substance
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody (human) 1 substance
Antimetabolite 1 substance
Alkylating agent 1 substance
Phase III: 10 Phase II: 6 Phase III/IV: 1 Phase I: 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

10 trials
  • Amgen Inc. Commercial
    OCRELIZUMAB
    2024-512914-16-00 15 countries 2025 n=375
    Ended
  • Biogen Idec Research Limited Commercial
    INTERFERON BETA-1A; PEGINTERFERON BETA-1A
    2023-505624-56-00 5 countries 2019 n=29
    Ended
  • Biogen Idec Research Limited Commercial
    DIMETHYL FUMARATE
    2023-505632-35-00 1 country 2014 n=37
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    OZANIMOD HYDROCHLORIDE
    2022-501332-42-00 5 countries 2025 n=38
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506467-34-00 10 countries 2020 n=357
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIMENHYDRINATE; FINGOLIMOD; METHYLPREDNISOLONE SODIUM SUCCINATE; OCRELIZUMAB
    2023-506516-40-00 17 countries 2022 n=94
    Ended
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-506543-41-00 14 countries 2018 n=645
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-513292-40-00 1 country n=250
    Pending
  • Helse Bergen HF Academic
    ALEMTUZUMAB; ANTITHYMOCYTE IMMUNOGLOBULIN; CLADRIBINE; CYCLOPHOSPHAMIDE; OCRELIZUMAB
    2024-510630-40-00 4 countries 2018 n=100
    Ended
  • Rigshospitalet Academic
    OCRELIZUMAB; RITUXIMAB
    2024-514287-84-00 1 country 2021 n=600
    Ended

Phase II

6 trials
  • F. Hoffmann-La Roche AG Commercial
    DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
    2023-507313-94-00 2 countries 2019 n=12
    Ended
  • Immunic AG Commercial
    VIDOFLUDIMUS CALCIUM
    2024-516739-29-00 4 countries 2019 n=142
    Recruiting
  • Zenas Biopharma (USA) LLC Commercial
    OBEXELIMAB
    2024-512707-40-00 10 countries 2024 n=93 Orphan
    Recruiting
  • Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S Academic
    ALEMTUZUMAB; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB
    2024-515470-26-00 1 country 2024 n=90
    Recruiting
  • Les Hopitaux Universitaires De Strasbourg Academic
    TESTOSTERONE UNDECANOATE
    2024-517845-14-00 1 country 2024 n=80
    Recruiting
  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Academic
    LACTOBACILLUS HELVETICUS, LACTOBACILLUS RHAMNOSUS, STRAIN LCR35, LIVE; OFATUMUMAB; OZANIMOD; OZANIMOD, OZANIMOD
    2025-520955-10-00 1 country n=210
    Not authorised

Phase III/IV

1 trial
  • CHU De Rouen Academic
    OCRELIZUMAB; RITUXIMAB
    2022-501027-25-01 1 country 2023 n=208
    Ended

Phase I

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 4 Phase II, Phase III 0
Biogen Idec Research Limited Commercial 2 Phase III 0
Cellerys AG Commercial 1 Phase I 0
Immunic AG Commercial 1 Phase II 1
Zenas Biopharma (USA) LLC Commercial 1 Phase II 1
Amgen Inc. Commercial 1 Phase III 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 1
CHU De Rouen Academic 1 Phase III/IV 0
Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S Academic 1 Phase II 1
Les Hopitaux Universitaires De Strasbourg Academic 1 Phase II 1
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Academic 1 Phase II 0
Centre Hospitalier Universitaire De Nantes Academic 1 Phase III 0
Helse Bergen HF Academic 1 Phase III 0
Rigshospitalet Academic 1 Phase III 0
New trials by year
2019
3
2020
1
2021
1
2022
1
2023
1
2024
4
2025
2
← All indication landscapes